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Summary
The epidemics of classical bovine spongiform encephalo-
pathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD)
related to BSE-infected food are coming to an end. The
decline in concern about these diseases may invite com-
placency and questions whether surveillance for human
prion diseases is still necessary. This article reviews the
main points of surveillance and why it is still needed: an-
imal sources for human prion infection other than BSE
cannot be excluded; the potentially increasing circulation
of prions between humans by blood, blood products and
medical procedures; the prevalence of vCJD prion carriers
in the UK; and the scientific study of prion diseases as
paradigm for other neurodegenerative diseases with “prion-
like” spread of pathological proteins. We conclude that
continuation of detailed surveillance of human prion disor-
ders would be prudent in view of all these points that de-
serve clarification.
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Abbreviations
BSE bovine spongiform encephalopathy
CJD Creutzfeldt-Jakob disease
CSF cerebrospinal fluid
EEG electroencephalogram
FFI fatal familial insomnia
GSS Gerstmann-Sträussler-Scheinker disease
gCJD genetic CJD
iCJD iatrogenic CJD
M methionine
MRI magnetic resonance imaging
PRNP prion protein gene
PrP prion protein
PrPres proteinase-resistant PrP
Rt-QuIC real-time quaking induced conversion
sCJD sporadic CJD
V valine
vCJD Variant CJD
VPSPr variably proteinase-sensitive prionopathy
WHO World Health Organization
Introduction
It was a veritable news bombshell when, in March 1996,
the UK Minister of Health announced the likely trans-
mission of the epidemic of bovine spongiform encephalo-
pathy (BSE) in cattle to humans, causing a new variant of
Creutzfeldt-Jakob disease (vCJD). Frantic efforts to con-
tain the damage already done included implementation of
CJD surveillance, not only in the UK and continental EU,
but in many other countries. Now, almost 20 years later,
this is already history, and present-day medical students
in Switzerland, and probably elsewhere, have little if any
knowledge of BSE and its aftermath. While this may be
partly attributed to the successful scientific and medical
management of BSE and its major problems [1], the de-
cline in concern about these diseases may invite compla-
cency and questions whether surveillance for human prion
diseases is still necessary. This article intends to explore
this in more depth and, not surprisingly in an article written
by two experts on surveillance of prion diseases, our an-
swer to the question posed in the title is yes.
National surveillance for human prion diseases was started
in several countries prior to 1996, but after the advent of
vCJD, surveillance systems were established in many EU
and some other countries to determine the extent to which
human exposure to BSE prions might affect national popu-
lations. Additional reasons included: assessment of the ef-
fects of costly management measures to stop entrance in-
to, and circulation within, the human food chain of bovine
prions; the need to have a human counterpart of the newly
established active surveillance for animal prion diseases,
which quickly showed a considerably more widespread
distribution of BSE than originally assumed; exploration of
the possibility that phenotypes other than vCJD might be
animal-derived; and identification as early as possible of
new mechanisms of iatrogenic transmission of human pri-
on diseases. In fact, the World Health Organization (WHO)
recommended global CJD surveillance at a consultation as
early as May 1996 [2], and emphasised the appropriate
methodologies for such surveillance at further meetings
and in publications [3]. The biggest obstacle to efficient
surveillance has been limited knowledge of the nature of
the causative agent, which has resulted in the absence of
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prion-specific tests comparable in validity and speed to mi-
crobiological tests for viruses or bacteria. In fact, the gold
standard for detecting the infectious agent in prion disease
has been transmission to experimental animals, which is
costly, laborious and takes several months to years to yield
results. Thus, in practice, up to now surrogate markers have
been increasingly used in diagnosis, case definitions and
surveillance.
The present BSE situation
Since the first observation in the UK of BSE as a novel pri-
on disease in cattle in November 1986, 184 511 indigen-
ous BSE cases had been diagnosed by April 2015, with a
peak in 1992 and 1993 of more than 35 000 cases annually,
representing incidence rates of more than 6 000 per million
in bovines over 24 months of age. Since then, the UK epi-
demic curve has been in spectacular decline, with single-
digit case numbers since 2011, only one case in 2014, and
so far two in 2015 (http://www.oie.int). A total of up to one
million infected cattle were estimated to have entered the
human food chain in the UK from 1980–1996. Far few-
er BSE cases have been diagnosed elsewhere, with one
or more annual incidence rates exceeding 10 per million
bovines over 24 months of age only in Belgium, the Czech
Republic, France, Germany, Ireland, Italy, Luxemburg, the
Netherlands, Portugal, Slovakia, Spain, and Switzerland,
where the outbreak was officially declared closed in 2011.
Worldwide BSE figures, however, have to be called into
question, as effective active surveillance programmes are
the prerequisite for adequate case ascertainment, but have
been fully implemented only in the EU, Canada, Japan,
and some other countries. Despite such geographical uncer-
tainty, it is clear that the present BSE situation is most fa-
vourable when “classical” BSE is considered, with the epi-
demic of BSE virtually extinct in the UK, EU, and Japan.
In contrast, “atypical” BSE continues to occur consistently
at very low rates, as it is likely a sporadic disease form
in analogy with sporadic CJD (sCJD). Atypical BSE has
been diagnosed in two forms, as H-type and L-type or
bovine amyloidotic spongiform encephalopathy (BASE);
according to transmission experiments to human prion pro-
tein (PrP) transgenic mice or primates, BASE in particular
might have zoonotic potential [4].
Surveillance
Case ascertainment
There are four main types of human prion disease: sporadic
CJD (sCJD), genetic or hereditary forms (gCJD), the zo-
onotic form vCJD and accidentally transmitted or iatro-
genic CJD (iCJD). In most countries carrying out national
surveillance for CJD, identification of patients depends on
notification of suspected cases by targeted professional
groups, including neurologists, neuropathologists and more
recently radiologists. Details of the clinical features and
investigations are obtained and cases are classified using
internationally accepted diagnostic criteria [3], which al-
lows valid comparisons of data on CJD between centres
and countries. The identification of sCJD and vCJD rely
on identification of the characteristic clinical phenotypes,
while diagnosis of hereditary forms of human prion disease
depends on sequencing of the prion protein gene (PRNP) to
identify disease-associated mutations, and in iCJD seeking
a history of specific causal exposures, e.g. human growth
hormone treatment or prior human dura mater graft.
Case definitions
Diagnostic criteria for all forms of CJD have been formu-
lated and partially validated [3]. These include a combin-
ation of key clinical features with the results of investig-
ations such as electroencephalogram, MRI brain scan and
cerebrospinal fluid (CSF) 14-3-3 bioassay to allow clas-
sification as “probable” or “possible” in life. A definite
diagnosis requires neuropathological confirmation, usually
after post-mortem examination. In general, official statist-
ics on CJD report only cases classified as “definite” or
“probable” as the true diagnosis in “possible” cases may be
uncertain.
Clinical features
The paradigm features of sCJD are rapidly progressive de-
mentia and myoclonic involuntary movements, associated
with focal neurological features such as ataxia. The mean
survival is short, which distinguishes sCJD from more
common forms of dementia. Terminally, sCJD is charac-
terised by a state of akinetic mutism with death usually
due to intercurrent illness such as pneumonia. In vCJD the
clinical course is more protracted with a mean survival of
14 months and, although the terminal stages are similar to
sCJD, with dementia, ataxia and involuntary limb move-
ments, there is a prodrome of psychiatric symptoms such as
depression and anxiety for a mean of 6 months before cog-
nitive and focal neurological features develop.
The clinical features of gCJD are heterogeneous and this is
determined largely by the specific associated PRNP muta-
tion. Some cases develop a syndrome very similar to sCJD,
while other cases present with nonspecific neurological
features such as a progressive ataxic syndrome or isolated
progressive dementia. In iCJD due to peripheral exposure
to infection, for example human growth hormone treat-
ment, there is a progressive ataxic syndrome, with little
evidence of cognitive impairment. With a central exposure,
for example to an infected human dura mater graft, the clin-
ical features are similar to sCJD.
Investigations
There is no diagnostic blood test for human prions and,
although specialist investigations are nonspecific in CJD,
they are nonetheless invaluable to diagnosis. The electroen-
cephalogram (EEG) shows periodic triphasic complexes in
a majority of cases of sCJD, but has largely been replaced
by the 14-3-3 cerebrospinal fluid (CSF) assay [5] and mag-
netic resonance imaging (MRI) brain scan, which shows
high signal in caudate, putamen and/or cortical regions in
about 80% of cases. The 14-3-3 assay is nonspecific, as it
is a marker of neuronal damage, and it may be replaced in
time with CSF real-time quaking induced conversion (Rt-
QuIC), which amplifies prion protein, but not infectivity, to
produce a fluorescent signal, and has a very high sensitiv-
ity and specificity in sCJD [6].
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In vCJD the most helpful test is the MRI brain scan, which
shows high signal in the posterior thalamus, the “pulvinar
sign”, in about 90% of cases by use of fluid-attenuated in-
version recovery (FLAIR) and diffusion-weighted imaging
(DWI) sequences. Tonsil biopsy to identify disease-associ-
ated prion protein can be a useful investigation in cases of
vCJD in which there is diagnostic uncertainty, but this in-
vestigation has risks, as does brain biopsy, which is rarely
carried out in CJD. The RT-QuIC is negative in vCJD using
current methodologies and the 14-3-3 assay is positive in
only about 50% of cases.
The MRI brain scan and 14-3-3 CSF assays can also be
helpful in the diagnosis of both gCJD and iCJD, and should
be considered in all CJD suspect cases. Most hospitals now
have an MRI scanner and there is no evidence of a risk
from carrying out CSF examination.
Neuropathology
A definite diagnosis of human prion disease requires
neuropathological confirmation and/or confirmation of
protease-resistant prion protein (PrPres) by immunocyto-
chemistry or Western blot [3]. Thus neuropathology is an
essential element of any surveillance system. Paramount
histological features are spongiform change, neuronal loss,
astro- and microgliosis and deposition of disease-associ-
ated PrP in affected CNS tissue [7]. However, each of these
features may be variably present and distinctly distributed,
giving rise to neuropathological heterogeneity that mirrors
that seen in clinical presentation. In fact, for sporadic CJD
(sCJD), such heterogeneity has been attributed to distinct
“strains” defined by two molecular determinants, the PRNP
polymorphism (methionine[M] vs valine [V]) at codon 129
on one hand, and to one of two types of PrPres demonstrable
by immunoblotting on the other. Thus neuropathology in-
cludes distinct profiles that distinguish at least six major
sCJD “histotypes” (MM or MV/1, VV1, MM2 cortical,
MM2 thalamic, MV2, VV2) and also mixed types [8, 9].
Immunohistochemical demonstration of disease-associated
PrP in sections of affected brain tissue is part of this hetero-
geneity, with distinct deposition patterns described as syn-
aptic, patchy-perivacuolar, pericellular, plaque-like or with
Kuru-type plaques [7].
Protein biochemistry
Western blotting to identify PrPres in affected brain tissue
usually complements the full diagnostic spectrum applic-
able in autopsy cases of human prion diseases. A brain
tissue homogenate is digested with proteinase K and im-
munoblotted with an anti-PrP antibody (mostly 3F4), re-
vealing three distinct PrPres bands representing di-, mono-
and unglycosylated protein fragments. However, banding
patterns of proteinase K digestion products do not strictly
correspond to differences in glycosylation degree but also
to chain length differences as shown with the POM an-
tibody family [10]. According to the size of the unglyc-
osylated fragment, PrPres is classified as type 1 (with a mo-
lecular size of 21 kDa) or type 2 (19 kDa), as the proteinase
K cleavage site differs between both types [9]. In vCJD,
a peculiar pattern, denoted as type 2B, has predominance
of the diglycosylated fragment in addition to an unglyc-
osylated fragment of 19 kDa, in contrast with type 2A seen
in sCJD with predominantly monoglycosylated PrPres. In
genetic prion diseases, however, the blotting patterns may
be more variable and reveal also lower size bands.
There are occasional cases in which such immunoblotting
is negative or equivocal at first hand. One condition more
recently described as variably proteinase-sensitive priono-
pathy (VPSPr) [11] may yield immunoblots that may be
negative when the anti-PrP 3F4 antibody is used, but show
a ladder-like pattern with other antibodies such as 1E4,
which is directed against PrP epitope 97-15. Moreover,
clinically probable or possible CJD cases found recently by
surveillance in Austria did not demonstrate any PrPres at all
by immunoblotting, but at autopsy thalamic degeneration
with a peculiar immunohistochemical pattern of PrP was
found[12]; however, the nosological position of this entity
still needs to be determined.
Genetics
More than 30 PRNP mutations or insertions have been
found associated with clinical manifestations that may be
similar to, or strikingly different from, sCJD [13]. For sur-
veillance, it is important to recognise the absence of a pos-
itive family history in about half of all genetic cases [14].
Thus genetic testing may be useful in all CJD-suspected pa-
tients, as a disease-associated aberration would dismiss fur-
ther diagnostic considerations. Moreover, knowledge of the
PRNP 129 M/V polymorphism is useful for further subtyp-
ing of sCJD [15].
Epidemiology
Sporadic CJD
Incidence and gender distribution
Sporadic CJD is by far the most common human prion dis-
ease, but is overall rare. Most established surveillance sys-
tems find sCJD at annual mortality rates between 1 and 2
per million [16]. However, there are considerable differen-
ces between countries, and a positive correlation between
incidence and surveillance intensity has been demonstrated
[17]. While some countries report differences in gender
distribution, this has not been consistent in international
studies, and only a slight increase of deaths in men over age
70 has been found [16].
Age distribution and duration of disease
Sporadic CJD is a disease mainly of the elderly, with a peak
between ages 60 to 79 years [16]. A decline over age 80
has been described [16], but it is unclear whether this might
be an artefact of previously incomplete case ascertainment
in the elderly [18]. Duration of disease is usually short,
with a median of 5 months [19], as reflected by the early
term of “subacute” spongiform encephalopathy. However,
longer survival has been found to correlate with younger
age at onset, female gender, heterozygosity at PRNP 129,
presence of CSF 14-3-3 protein and type 2A PrPres [19].
Geographical distribution
In countries on different continents with well-established
surveillance, sCJD has been shown to occur at similar rates
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[16]. Thus it seems that globally it is relatively evenly dis-
tributed.
Risk factors
Case-control studies in sCJD have produced varying results
but no consistent risk factor for the development of disease
has been identified. Notably, there is no evidence of direct
spread of infection from person to person or of an increased
risk through occupation, for example in medical or para-
medical professions [20]. An increased risk through prior
surgery has been found in one study [21], but not others,
and the evidence overall, including look-back studies, does
not suggest that having received a blood transfusion in-
creases the risk of the disease.[22] Although many of the
studies of risk factors in sCJD may be subject to bias or
confounding [23], the findings are consistent with the hy-
pothesis that sCJD is not an environmentally acquired dis-
ease.
Variably proteinase-sensitive prionopathy (VPSPr)
VPSPr was recently described as a new but rare type of
sporadic prion disease that occurs in all genotypes of the
PRNP 129 polymorphism, although V129V is most com-
mon [11]. Most cases have occurred in the USA, with a few
cases most recently found also in Europe. For surveillance,
VPSPr might pose a problem because of the peculiar prop-
erties of its disease-associated PrP (see above) when dia-
gnosis relies on immunoblotting only. However, neuropath-
ology is able to recognise a prion disease because of some
spongiform change and positive immunohistochemistry for
PrP, although the presence of microplaques is peculiar [11].
Variant CJD
Incidence and geographic distribution
Variant CJD was identified in the UK in 1996 and has an
overall mortality rate of 0.15/million. Cases of vCJD have
been identified in a number of other countries, mainly in
Europe (table 1), most likely through exposure to BSE in-
fection through UK exports rather than indigenous BSE. It
is of note that there is international agreement that cases of
vCJD are classified according to the country of normal res-
idence at the time of disease onset and there are, therefore,
cases in which the country of exposure to BSE in not the
same as the country of attribution, for example the cases in
the USA.
Age distribution
Variant CJD affects a younger age group than sCJD with
a mean age at death of 28 years in comparison with 66
years in sCJD. The reason for the young age in vCJD is
unknown, but possibilities include age-related susceptibil-
ity to infection or variation in exposure to BSE in the food
chain according to age group.
Epidemic curve
Initial fears of a massive epidemic of vCJD have not ma-
terialised; the outbreak, having peaked in 2000, is now in
decline and there have been no new cases in the UK since
2013. Cases of vCJD outside the UK are also in decline
(fig. 1). There was an extensive exposure of the UK popu-
lation to BSE in the food chain and the likely explanation
of the limited epidemic of vCJD is that there is a substan-
tial species barrier between bovines and humans [24].
Risk factors
The major risk factor for vCJD is a history of residence
in the UK, which is consistent with BSE as the cause of
this disease. The other important determinant is the PRNP
codon 129 polymorphism, as all tested probable and defin-
ite clinical cases have been methionine homozygotes at this
locus (the distribution of PRNP 129 genotypes in the nor-
mal population is about 51% MV, 37% MM, and 12% VV).
There are concerns that further outbreaks may appear at a
later date in the alternative codon 129 genotypes. A case-
control study in vCJD, which showed an increased risk
through consumption of food potentially containing high
levels of BSE infectivity, is consistent with the hypothesis
of food born transmission of infection [25].
Prevalence studies
There is a significantly higher level of disease-associated
prion protein in peripheral tissues such as the lymphore-
ticular system in vCJD as compared with sCJD. This has
led to pathological studies in the UK of routine tonsil and
appendix specimens to determine whether members of the
general population may be infected with BSE, but showing
no symptoms. In prion disease there is a silent incubation
period between exposure to infection and the development
of symptoms, which is estimated to be around a mean of 15
years in vCJD. A recent study found 16 positive appendix
specimens in over 32 000 samples, leading to an estimated
prevalence of infection of 1/2 000 [26], suggesting a signi-
ficant fraction of the UK population with a carrier state.
Secondary transmission
The significant peripheral pathogenesis in vCJD led to con-
cerns that this condition might be transmissible through
blood transfusion and a look-back study was established in
the UK in 1996. In 2003 a case of vCJD was identified with
a history of having received a blood transfusion donated
by an individual who themselves later developed vCJD.
Since then two further clinical cases have been linked to
a blood transfusion derived from another case, providing
strong evidence that this condition can be transmitted via
blood transfusion [23, 27]. In addition one recipient who
died of a non-neurological illness was found to have abnor-
mal prion protein in the spleen and a lymph node, and a pa-
Figure 1
Variant Creutzfeldt Jakob disease cases by year and country:
1994-2015 (n = 229).
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tient with haemophilia, treated with UK plasma products,
had a positive Western blot in a spleen sample.
Iatrogenic CJD
Incidence
About 3% of all cases of CJD are iatrogenic in origin, but
the incidence varies markedly from country to country in
relation to differences in medical and surgical practice and
the source of medical treatments such as human pituitary
derived hormones.
Sources of infection
The main types of iCJD numerically are cases caused by
surgical treatment with human dura mater grafts, partic-
ularly the brand Lyodura® (n = >220 cases) and cases
caused by treatment in childhood with human pituitary
growth hormone (n = >220). The presumption is that tis-
sues derived from cases of sCJD were included in the pro-
duction process, contaminating the final product with in-
fectivity. Rarer causes of iCJD include six cases caused
by infected neurosurgical instruments or EEG depth elec-
trodes, two linked to corneal grafts and four linked to hu-
man pituitary gonadotrophin treatment [28]. Transfusion
transmission of vCJD is described above.
Incubation period
The interval between exposure to a treatment and the de-
velopment of clinical symptoms can be accurately determ-
ined in iCJD cases linked to specific surgical procedures:
with human dura mater grafts the mean incubation period
is 12 years and with surgical instruments 1–2 years. In hu-
man growth hormone cases the incubation period estimates
are made in relation to the mid-point of treatment, which
sometimes extended to many years, and the mean incuba-
tion period in these cases is estimated to be 17 years. In the
more common forms of iCJD there is a wide spread of in-
cubation periods, which can range from 1 to more than 40
years. In transfusion transmitted vCJD the incubation peri-
od ranges from 3–8 years.
Geographic distribution
Cases of iCJD have been identified in 21 countries, but
there is a clear excess of cases linked to human dura mater
grafts in Japan, probably because these grafts were used
more frequently in Japan than other countries. More than
half the total human growth hormone cases have been in
France, possibly because of a higher level of contamination
in the production process.
Genetic prion diseases
Incidence
About 10 to 15% of prion diseases in Caucasians have a
genetic origin. In the series of the EuroCJD consortium,
10.2% of all cases were genetic, but with considerable dif-
ferences between countries [14]. The responsible PRNP ab-
errations and their clinicopathological correlates have been
amply described, e.g. in [13]. In addition to gCJD (with
E200K as most frequent) that usually mimics sCJD, dis-
tinct phenotypes include Gerstmann-Sträussler-Scheinker
disease (GSS, with P102L as the most frequent mutation),
classically with a slowly evolving spinoataxic syndrome
and neuropathologically pathognomonic multicentric PrP
plaques; fatal familial insomnia (FFI, with D178N M129M
as the most frequent constellation and predominantly
thalamic degeneration); and a novel systemic PrP amyl-
oidosis with Y163X [13]. Sporadic fatal insomnia (SFI) is
a very rare peculiar clinical-pathological phenotype that is
indistinguishable from FFI, but the FFI-associated PRNP
aberration is absent.
Age distribution and duration of disease
GSS and FFI usually manifest earlier than gCJD or sCJD
and have a longer disease duration [14]. Insert mutations
may have a gCJD or GSS phenotype and are variable in age
at onset and duration of disease [14].
Geographic clusters
Israel (mainly Sephardic Jews emigrating from Libya) and
Slovakia (preferentially the Orava and Lucenec provinces)
have a high prevalence of the E200K mutation that mani-
fests mostly indistinguishably from sCJD [14]. In Italy, the
Table 1: Variant Creutzfeldt-Jakob disease - current data: August 2015.
Country Total number of primary cases
(number alive)
Total number of secondary cases
(number alive)
Residence in the UK >6 months during
period 1980–1996
UK 174 (0) 3 (0) 177
France 27 (0) – 1
Republic of Ireland 4 (0) – 2
Italy 2 (0) – 0
USA 42 (0) – 2
Canada 2 (0) – 1
Saudi Arabia 1 (0) – 0
Japan 11 (0) – 0
Netherlands 3 (0) – 0
Portugal 2 (0) – 0
Spain 5 (0) – 0
Taiwan 1 (0) – 1
1 The case from Japan had resided in the UK for 24 days in the period 1980–1996.
2 The third US patient with vCJD was born and raised in Saudi Arabia and has lived permanently in the United States since late 2005. According to the US case-report, the
patient was most likely infected as a child when living in Saudi Arabia. In the fourth US patient the history indicated that exposure to infection most likely occurred prior to
moving to the USA.
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number of genetic cases was higher in Campania and Ca-
labria regions than in other regions [29].
Kuru
As with classical BSE, Kuru is now largely a matter of
medical history. This epidemic of the 20th century in the
Fore linguistic group of Papua-New Guinea was caused by
ritual cannibalism that was stopped in the late 1950s. Cases
are, however, still occurring with incubation periods ex-
ceeding 40 years [30]. The clinical presentation was with
an ataxic syndrome and death followed in 12–18 months.
Kuru has taught the medical and scientific community sev-
eral lessons about external prion infection in humans, in-
cluding the length of incubation time, the absence of ver-
tical transmission from mother to child and the role of the
genetic background, with the recent finding of a human
PRNP polymorphism that completely protects against in-
fectious prions [31]. It seems that Kuru acted as a selection
factor for a resistance genotype in Kuru-affected regions.
Kuru was the first prion disease to be experimentally trans-
mitted in a laboratory setting, a finding that led to success-
ful experimental transmission of sCJD.
Conclusions
It is obvious that the epidemic of classical BSE is coming
to an end. However, atypical BSE is expected to persist,
possibly as a sporadic disease, and recent experimental data
on the transmission of classical sheep scrapie strains to hu-
manised mice [32] and primates [33] are questioning the
traditional belief that prion diseases of small ruminants do
not have zoonotic potential. Thus, even in the absence of
BSE, the possibility of a remaining animal source for hu-
man prion diseases cannot be excluded and this should
stimulate continued research and analysis. Moreover, the
threat of circulation of prions between humans, from ex-
ternal sources or by iatrogenic procedures including blood/
blood product therapies, must also be considered, an issue
highlighted by the prevalence data on vCJD infection in the
UK that suggest a significant fraction with a carrier state of
the population. Finally, prion diseases have more recently
served as the gold standard paradigm to compare with the
“prion-like” spread of other aggregated proteins in neuro-
degenerative diseases. It remains to be seen whether a nov-
el public health hazard is emerging from diseases that are
several logs more frequent in the population. Continuation
of detailed surveillance of human prion disorders would be
prudent in view of all these issues that deserve clarifica-
tion, together with research into the potential transmissibil-
ity of other neurodegenerative diseases. Moreover, it would
be wise to maintain well-organized surveillance structures
for human prion diseases: it is easy to destroy function-
ing structures, but it is extremely difficult and expensive to
build up novel structures.
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Figures (large format)
Figure 1
Variant Creutzfeldt Jakob disease cases by year and country: 1994-2015 (n = 229).
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